In patients with stage 3/4 CKD and with heart failure (HFpEF), SGLT2 inhibitors significantly decreased the risk of the primary cardiovascular outcome (Fig 4, HR 0.72, [95% CI 0.56–0.93], I2 = 37.23%). This evidence concerns the gene SLC5A2 and chronic kidney disease.